ASH 2024 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in CLL.
I tried the new AI scan for skin cancer with results in 30 seconds — and it's better than a dermatologist - The Skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback